Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
4fuqQMTvktS6Qsqc
